11/02/2019 23:14:16

Veritas Pharma Announces the Resignation of CEO, Dr. Lui Franciosi

VANCOUVER, British Columbia, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces the resignation of its President, CEO and Director, Dr. Lui Franciosi.  Company Interim CFO, Mr. Peter McFadden will fill the executive roles in the interim until a qualified replacement is found.

Dr. Franciosi stated, “It has been a challenging year with the regulatory delays in starting the Puerto Rico human study of CTL-X and the need to raise funds for medical cannabis research.  I am pleased to see the study approval has finally come through and that potential funding for Cannevert’s important scientific work has been secured, which means that the Veritas and Cannevert are now set for growth under new leadership. My work with Veritas has been a great experience, however I am extremely excited to give my primary focus to the science side of the business, and I will be available to the company at an advisory capacity to ensure seamless transition.”

Mr. McFadden stated, “The Veritas Board would like to thank Lui for his commitment to investors and to advancing the science behind medical cannabis.”  Dr. Franciosi will continue to assist both companies in an operational capacity.

About Veritas Pharma Inc.

Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 100% owned subsidiary Cannevert Therapeutics Ltd. (“CTL“), is advancing the science behind medical cannabis. It is the Company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas’ investment in CTL is led by a strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion-dollar markets according to Deloitte’s Insights and Opportunities.

Veritas Pharma Inc. is a publicly traded company in Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

For more information, please visit our website: www.veritaspharmainc.com

On behalf of the Board of Directors

"

Mr.

Peter McFadden"

Mr. Peter McFadden

Interim President and Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.

Contact

Investor and Public Relations

at:

Telephone: +1.604.827.5520

Email: ir@veritaspharmainc.com

Website: www.veritaspharmainc.com

The CSE has not reviewed, nor approved or disapproved the content of this press release.

Logo.PNG

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Aug
VELO
Da flere skribenter stadig gerne vil beholde tråden for samling af de mange vigtige informationer o..
43
15 Aug
VELO
Det kunne tyde på at nogen mor modtaget receptal, der udviser netop det vi har talt om - at Envarsus..
37
19 Aug
OMXC25
Endnu en dansk patriark er død. Ære være hans minde.
26
18 Aug
 
Da Berlingske Media for cirka 1 år siden overtog Euroinvestor for 23 mio kr, meddelte de, at nu skul..
22
18 Aug
VELO
Fra anden skribent i Veloxis FB gruppen: Børsen side 4, søndag den 18. august. Et uddrag fra e..
20
16 Aug
I:NDX
16
14 Aug
TEVA
Ja, TEVA er jo bare en dårlig historie at købe ind i. I Danmark er aktien (som alle jo ved) primært ..
16
13 Aug
VELO
Til alle dem, som simpelthen ikke kan tro på det der sker lige foran næsen på dem.    Da jeg i sin b..
16
19 Aug
OMXC25
En fantastisk dygtig og sympatisk erhvervsmand.  Og en ægte patriot som også betalte sin skat med gl..
15
18 Aug
VELO
'83. Det er en god kommentar, iøvrigt har jeg kontaktet DDB i fredags for at høre om de læser recept..
15

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Photo Release -- WSFS Bank Welcomes Corynn Ciber in Newly Created Role, Chief Digital Officer
2
TTM Technologies, Inc. Announces Executive Transition
3
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eagle Bancorp, Karyopharm, L Brands, and National General and Encourages Investors to Contact the Firm
4
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Curaleaf and Encourages Investors to Contact the Firm
5
Hagens Berman Investigating SAExploration Holdings (SAEX): Earnings Restatements, SEC Investigation, and Senior Executives Fired

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 August 2019 00:24:10
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB6 - 2019-08-20 01:24:10 - 2019-08-20 00:24:10 - 1000 - Website: OKAY